Genmab AS is a biotechnology business based in the US. Genmab AS shares (GMAB) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $19.36 – a decrease of 10.16% over the previous week. Genmab AS employs 2,682 staff and has a trailing 12-month revenue of around $21.5 billion.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $19.36 |
|---|---|
| 52-week range | $17.24 - $30.41 |
| 50-day moving average | $20.44 |
| 200-day moving average | $22.62 |
| Wall St. target price | $29.50 |
| PE ratio | 10.5217 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $1.84 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $19.36 from 2025-05-09
| 1 week (2025-05-05) | -10.16% |
|---|---|
| 1 month (2025-04-11) | 2.92% |
| 3 months (2025-02-13) | -7.46% |
| 6 months (2024-11-13) | -10.62% |
| 1 year (2024-05-13) | -33.61% |
|---|---|
| 2 years (2023-05-11) | -53.86% |
| 3 years (2022-05-11) | 27.98 |
| 5 years (2020-05-11) | 28.25 |
Valuing Genmab AS stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Genmab AS's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Genmab AS's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, Genmab AS shares trade at around 11x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Genmab AS's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.0203. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Genmab AS's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Genmab AS's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $7.4 billion.
The EBITDA is a measure of a Genmab AS's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $21.5 billion |
|---|---|
| Operating margin TTM | 35.2% |
| Gross profit TTM | $20.5 billion |
| Return on assets TTM | 10.91% |
| Return on equity TTM | 22.97% |
| Profit margin | 36.44% |
| Book value | $577.54 |
| Market Capitalization | $12.1 billion |
TTM: trailing 12 months
We're not expecting Genmab AS to pay a dividend over the next 12 months.
Genmab AS's shares were split on a 5:1 basis on 30 April 2018 . So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Genmab AS shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Genmab AS shares which in turn could have impacted Genmab AS's share price.
Over the last 12 months, Genmab AS's shares have ranged in value from as little as $17.235 up to $30.41. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genmab AS's is 0.901. This would suggest that Genmab AS's shares are less volatile than average (for this exchange).
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc. , Pfizer Inc.
We dug through 60 years of Berkshire Hathaway annual shareholder letters to bring you 9 lessons from Warren Buffett: “The Oracle of Omaha.”
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Thinking of switching from Moomoo? Here are 5 apps like Moomoo that offer valuable benefits
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Webull is a broker with zero-commission trading and a suite of tools to help you invest.
Here’s what you need to know about how to buy and sell stocks online in this easy to follow, step-by-step guide.